

To: The Joint Committee on Marijuana Regulation,
Honorable Co-Chairs Burdick and Lininger, and the Joint Committee,

I am Michael D. Rochlin, RN, MN, CSP, COHN-S. I own MJ Enterprises, LLC, a Cannabis Consulting and advocacy Company in Oregon. I have appeared before you many times, since M91 passed in 2014.

I specialize in Environment Health & Safety and have managed complex medical cases involving pain, with Cannabinoid Therapeutics. I have been collaborating with an Oregon-based family of Functional Medicine Physicians who provide individualized Cannabinoid therapeutics.

We support HB 2198; renaming OLCC to include Cannabis Commission, and it is expected the Commission to be more proactive collecting, analyzing and producing meaningful data on current and foreseeable issues, incidents and benefits, of both therapeutic and adult Cannabis use.

Medical use and research of Cannabis therapeutics has been oppressed for decades, and this newly created Cannabis Commission is expected to be less bounded by obsolete and punitive narratives, and more open to finding out where the data will lead us.

One primary concern is statewide collection of real-time facts and data, so that emergent issues could be reviewed in a more collaborative and rationale manner, than a reactive one. It is hoped that the Cannabis Commission will collaborate with some of the current scientists and other states, in order to improve timely communication and leverage scarce resources.

Baselines of plant and product constituents, characteristics and clinical information need to be standardized, in order to determine if there are real potential harms or not to humans.

There are significant pre-clinical and some very high quality clinical studies that demonstrate practical benefits, as well as less adverse events over single-component pharmaceuticals.

Please pass this bill to the floor and help validate benefits and determine what actual harm might be realistically expected from Cannabis.

Oregon has a long history of craft growers, and we need to capture their knowledge about the therapeutic uses, before it's too late.

Michael D. Rochlin, RN, MN, CSP, COHN-S
DBA MJ Enterprises, LLC
206-427-1048
MDRochlin@gmail.com